Status:
COMPLETED
The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.
Lead Sponsor:
Menoufia University
Conditions:
Gouty Arthritis
Eligibility:
All Genders
35-65 years
Phase:
NA
Brief Summary
Objective: To study the impact of metformin on the outcome of gouty arthritis in a cohort of Egyptian gouty patients, and to evaluate its effect on local joint inflammation, inflammatory cytokines (I...
Detailed Description
Background: Metformin has anti-inflammatory properties, as it suppresses the inflammatory process by down-regulating the transcription factor, nuclear factor kappa B (NF-kB), through AMP-activated pro...
Eligibility Criteria
Inclusion
- gouty patients who fulfilled the American College of Rheumatology clinical criteria.
- gouty patients with active inflammatory arthritis.
Exclusion
- Patients with any type of inflammatory arthritis.
- Patients with systemic disease as diabetes, hypertension,
- Patients with hyperlipidemia, coronary artery disease,
- Patients with renal or hepatic insults,
- pregnant and lactating females
Key Trial Info
Start Date :
June 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05332795
Start Date
June 28 2022
End Date
February 20 2024
Last Update
March 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dalia Salah Saif
Menoufia Governorate, MD, Egypt, 123455